* Amylin Pharmaceuticals Inc., of San Diego, entered into a two-year agreement with Systems Integration Drug Discovery Co. Inc., of Tucson, Ariz., to support Amylin's discovery of drugs for metabolic diseases. Amylin will have access to chemical libraries to be synthesized by SIDDCO, to which Amylin has agreed to pay research support and milestones. SIDDCO uses combinatorial chemistry and miniaturized high-throughput assay technologies for drug discovery.

* Biomune Systems Inc., of Salt Lake City, exercised its option to purchase Rockwood Investments Inc., of Los Angeles, from Ira Ritter, the company's president. The price is $5.96 million plus warrants to purchase shares of Biomune's common stock. Rockwood markets and distributes health and cosmetic products.

* ChemTrak Inc., of Sunnyvale, Calif., received FDA clearance to market a new point-of-care quantitative assay for theophylline, called the Accumeter Theophylline Test. Theophylline is used as a bronchodilator and respiratory stimulant for asthma sufferers, and blood serum concentrations must be monitored to ensure optimal dosing while reducing side effects. The Accumeter test is a single-dose, disposable test that measures theophylline in the blood with 99 percent accuracy.

* SYNSORB Biotech Inc., of Calgary, Alberta, received $5 million from The Erin Mills Investment Corp., a privately held venture capital firm based in Concord, Ontario. Erin Mills exercised a warrant to acquire 1 million shares. The conversion raises the number of shares outstanding in SYNSORB to 18.7 million.

* T Cell Sciences Inc., of Needham, Mass., signed an agreement with Repligen Inc., also of Needham, to utilize T Cell's screening and functional assay technology to identify small-molecule immunoregulatory therapeutic compounds using Repligen's combinatory chemical library. The agreement will seek therapeutics for indications that include organ transplantation, rheumatoid arthritis and asthma. The most advanced of T Cell's current programs focuses on developing compounds to inhibit the inappropriate activation of the complement cascade in a variety of chronic and acute diseases.

* Vysis Inc., of Downers Grove, Ill., a genomics diagnostics company, signed a non-exclusive comarketing agreement with Irvine Scientific Sales Co. Inc., of Santa Ana, Calif., to distribute Irvine's line of cytogenetics tissue culture products. Vysis develops, commercializes and markets products for evaluating and managing cancer, prenatal disorders and other genetic diseases. Terms of the deal were not disclosed.

No Comments